Recursion Pharmaceuticals (RXRX) Total Liabilities (2020 - 2026)

Recursion Pharmaceuticals' Total Liabilities history runs 7 years deep, the most recent figure standing at $314.8 million for Q1 2026.

• Quarterly Total Liabilities fell 15.23% year-over-year to $314.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314.8 million (down 15.23% YoY) and the FY2025 annual result came in at $343.3 million, down 17.05% from the prior year.
• Total Liabilities was $314.8 million for Q1 2026 at Recursion Pharmaceuticals, down from $343.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $413.8 million in Q4 2024 and bottomed at $156.7 million in Q1 2024.
• A 5-year average of $260.1 million and a median of $223.5 million in 2022 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 324.89% — and 2024, when it retreated 20.54%.
• Recursion Pharmaceuticals' Total Liabilities stood at $215.5 million in 2022, then retreated by 11.7% to $190.3 million in 2023, then jumped by 117.5% to $413.8 million in 2024, then retreated by 17.05% to $343.3 million in 2025, then retreated by 8.31% to $314.8 million in 2026.
• Business Quant data shows RXRX's Total Liabilities at $314.8 million in Q1 2026, $343.3 million in Q4 2025, and $352.6 million in Q3 2025.